Literature DB >> 10380235

Prescription data as a tool in pharmacotherapy audit (I). General considerations.

C S de Vries1, T F Tromp, W Blijleven, L T de Jong-van den Berg.   

Abstract

This article discusses how prescription data that are available from pharmacies can be used as a tool to support the improvement of prescribing behaviour. For the optimal use of prescription data in pharmacotherapeutic audit, the specific aim of the audit meeting must be clear. Next, appropriate measures (quality of drug choice, volume, cost) have to be selected for the presentation and discussion of prescribing. For several aims of audit meetings, suggestions for adequate measures are given. For each stage of behavioural change the article describes why and how prescription data can provide a useful contribution. Finally, recommendations are given regarding prerequisites for the optimal use of prescription data. Important factors are that the prescription data should sufficiently cover the physicians' patient population, information regarding the extent of repeat prescribing is needed, and the prescribing of drugs with multiple indications can cause difficulties with the interpretation of the graphs. With this information in mind, feedback on prescribing can be tailored to the audit groups' needs and targeted to the intervention that is pursued.

Entities:  

Mesh:

Year:  1999        PMID: 10380235     DOI: 10.1023/a:1008617832536

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  29 in total

1.  The defined daily dose system (DDD) for drug utilization review.

Authors:  A I Wertheimer
Journal:  Hosp Pharm       Date:  1986-03

2.  Radical reforms for primary health care in New Zealand.

Authors:  L Malcolm
Journal:  World Health Forum       Date:  1995

3.  [The effect of admission to a geriatric department of a general hospital on drug consumption of the elderly].

Authors:  C J Haagsma; F W Gribnau; E Bruyns
Journal:  Ned Tijdschr Geneeskd       Date:  1989-11-25

4.  Specific therapeutic group age-sex related prescribing units (STAR-PUs): weightings for analysing general practices' prescribing in England.

Authors:  D C Lloyd; C M Harris; D J Roberts
Journal:  BMJ       Date:  1995-10-14

5.  Alterations in prescribing by general practitioner fundholders: an observational study.

Authors:  R P Wilson; I Buchan; T Walley
Journal:  BMJ       Date:  1995-11-18

6.  Shifting the balance from secondary to primary care.

Authors:  A Coulter
Journal:  BMJ       Date:  1995-12-02

7.  Off the prescription pad and over the counter: the trend toward drug deregulation grows.

Authors:  P P Morgan; L Cohen
Journal:  CMAJ       Date:  1995-02-01       Impact factor: 8.262

8.  The German health care system at the crossroads.

Authors:  J M vd Schulenburg
Journal:  Health Econ       Date:  1994 Sep-Oct       Impact factor: 3.046

9.  Measuring prescribing: the shortcomings of the item.

Authors:  S M Bogle; C M Harris
Journal:  BMJ       Date:  1994-03-05

10.  Comparison of admission and discharge medications in two geriatric populations.

Authors:  N Alexander; J S Goodwin; C Currie
Journal:  J Am Geriatr Soc       Date:  1985-12       Impact factor: 5.562

View more
  3 in total

Review 1.  Prescription data as a tool in pharmacotherapy audit (II). The development of an instrument.

Authors:  C S de Vries; P B van den Berg; J W Timmer; A Reicher; W Blijleven; T F Tromp; L T de Jong-van den Berg
Journal:  Pharm World Sci       Date:  1999-04

2.  Comparison of indicators assessing the quality of drug prescribing for asthma.

Authors:  C C Veninga; P Denig; L G Pont; F M Haaijer-Ruskamp
Journal:  Health Serv Res       Date:  2001-04       Impact factor: 3.402

3.  Prescribing indicators. Development and validation of guideline-based prescribing indicators as an instrument to measure the variation in the prescribing behaviour of general practitioners.

Authors:  Paul E M Muijrers; Rob Janknegt; Jildou Sijbrandij; Richard P T M Grol; J André Knottnerus
Journal:  Eur J Clin Pharmacol       Date:  2004-10-26       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.